Giardiasis and Cryptosporidiosis - Recent Literature with a Focus on Nitazoxanide
- *Corresponding Author:
- Steven Czinn
Professor and Chair, Department of Pediatrics
University of Maryland School of Medicine
Physician-in-Chief, University of Maryland Children's Hospital
22 South Greene Street, Room N5E17, Baltimore
Maryland 21201-1595, USA
Received Date: September 03, 2015; Accepted Date: October 02, 2015; Published Date: October 05, 2015
Citation: Blanchard SS, Gold BD, Czinn S (2015) Giardiasis and Cryptosporidiosis - Recent Literature with a Focus on Nitazoxanide. Pediat Therapeut 5:265. doi:10.4172/2161-0665.1000265
Copyright: © 2015 Blanchard SS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Nitazoxanide is a Food and Drug Administration approved Thiazolide to treat parasitic infections such as giardiasis and cryptosporidiosis. Since nitazoxanide is available as a liquid suspension, this medication is uniquely suited for the treatment of children. However, there has been a paucity of published studies since its approval. We completed a systematic literature search using a variety of sources including PubMed to identify studies reporting the impact of nitazoxanide in treating parasitic infections in children ages 1 to 11 years. A similar search was conducted on other available treatment for parasitic infection. In total, 28 publications were found to meet the criteria above for nitazoxanide. A similar number of papers were identified to address other therapy commonly used regardless of product information on approved use. Despite the ease of administration and superiority of nitazoxanide to other Non FDA approved therapies for the treatment of Giardia or Cryptosporidium among children, this medication continues to be underutilized. These data indicated the need for additional clinical studies to raise awareness.